Form 4: Aptevo Therapeutics Director Converts Restricted Stock Units to Common Shares

Aptevo Therapeutics Inc. Director John Niederhuber converted 1 post-split Restricted Stock Unit into common stock on July 17, 2025, following a grant made on July 17, 2024.

Summary

• John Niederhuber, a Director of Aptevo Therapeutics Inc. (APVO), reported a transaction on July 17, 2025.
• The transaction involved the conversion of 1 Restricted Stock Unit (RSU) into 1 share of Aptevo Therapeutics Common Stock.
• These RSUs were originally granted on July 17, 2024, with 925 RSUs granted, which became 1 RSU post-stock splits.
• The RSUs vested in full one year from the grant date.

Sentiment

Score: 5

Explanation: The transaction is a routine RSU conversion, which is a neutral event. While it represents a director increasing direct ownership, the extremely small number of shares (1 post-split) resulting from a prior 925 RSU grant suggests a significant reverse stock split, which can be a negative signal about the company's past performance or stock price health, offsetting any positive sentiment from insider ownership.

Positives

• A director converting RSUs to common stock can signal continued alignment of interests with shareholders.
• The transaction represents an increase in direct beneficial ownership of common stock by a director.

Negatives

• No explicit negatives are stated in this filing; the transaction itself is a routine RSU conversion.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The filing indicates the vesting schedule for previously granted Restricted Stock Units, with the conversion occurring one year after the grant date.

Industry Context

This filing is a standard disclosure of an insider equity transaction, common in the biotechnology or pharmaceutical industry for executive and director compensation.

Comparison to Industry Standards

• The grant and vesting of Restricted Stock Units (RSUs) as part of director compensation is a common practice across various industries, including biotechnology, aligning director incentives with long-term shareholder value.
• The conversion of 1 post-split RSU, which originated from 925 RSUs, indicates a significant reverse stock split by Aptevo Therapeutics Inc. (APVO). Such splits are often undertaken by companies, particularly in the biotech sector, to increase share price and meet listing requirements, which can sometimes signal underlying financial challenges or a need to improve stock perception, contrasting with companies that achieve higher share prices through organic growth.

Stakeholder Impact

• Shareholders: The conversion of RSUs into common stock by a director aligns their interests with shareholders, potentially signaling confidence in the company's future.

Key Dates

Recommendation

Keywords

Aptevo Therapeutics, APVO, Form 4, Insider Trading, Restricted Stock Units, RSU Conversion, Director Ownership, Equity Compensation